Apeloa Pharmaceutical's Subsidiary Secures European CEP for Gabapentin API

Stock News07-22

An announcement from Apeloa Pharmaceutical Co.,Ltd. (SZSE: 000739) reveals that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., has recently received a Certificate of Suitability to the European Pharmacopoeia (CEP) for the active pharmaceutical ingredient Gabapentin from the European Directorate for the Quality of Medicines & HealthCare (EDQM).

Gabapentin is a synthetically produced amino acid that is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA). Its approved indications include: 1. Postherpetic neuralgia: for the treatment of postherpetic neuralgia in adults; 2. Epilepsy: as adjunctive therapy for the treatment of partial seizures, with or without secondary generalization, in adults and children aged 12 years and older. It is also indicated as adjunctive therapy for partial seizures in children aged 3 to 12 years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment